

Diana Karpman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1062802/publications.pdf>

Version: 2024-02-01

100
papers

6,567
citations

53660

45
h-index

64668

79
g-index

105
all docs

105
docs citations

105
times ranked

5736
citing authors

#	ARTICLE	IF	CITATIONS
1	An international consensus approach to the management of atypical hemolytic uremic syndrome in children. <i>Pediatric Nephrology</i> , 2016, 31, 15-39.	0.9	445
2	Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. <i>Pediatric Nephrology</i> , 2009, 24, 687-696.	0.9	315
3	Extracellular vesicles in renal disease. <i>Nature Reviews Nephrology</i> , 2017, 13, 545-562.	4.1	238
4	Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. <i>Pediatric Nephrology</i> , 2019, 34, 11-30.	0.9	230
5	Pathogenesis of Shiga Toxin-Associated Hemolytic Uremic Syndrome. <i>Pediatric Research</i> , 2001, 50, 163-171.	1.1	180
6	Interleukin 8 Receptor Deficiency Confers Susceptibility to Acute Experimental Pyelonephritis and May Have a Human Counterpart. <i>Journal of Experimental Medicine</i> , 2000, 192, 881-890.	4.2	175
7	Lipopolysaccharide from enterohemorrhagic <i>Escherichia coli</i> binds to platelets through TLR4 and CD62 and is detected on circulating platelets in patients with hemolytic uremic syndrome. <i>Blood</i> , 2006, 108, 167-176.	0.6	166
8	Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic <i>Escherichia coli</i> -induced hemolytic uremic syndrome. <i>Blood</i> , 2011, 117, 5503-5513.	0.6	163
9	Apoptosis of Renal Cortical Cells in the Hemolytic-Uremic Syndrome: In Vivo and In Vitro Studies. <i>Infection and Immunity</i> , 1998, 66, 636-644.	1.0	161
10	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2008, 45, 95-105.	1.0	136
11	Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. <i>Blood</i> , 2008, 111, 5307-5315.	0.6	128
12	Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome. <i>Blood</i> , 2001, 97, 3100-3108.	0.6	127
13	Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. <i>Pediatric Nephrology</i> , 1995, 9, 694-699.	0.9	124
14	Reduced Toll-Like Receptor 4 Expression in Children with Asymptomatic Bacteriuria. <i>Journal of Infectious Diseases</i> , 2007, 196, 475-484.	1.9	113
15	Shiga Toxin and Lipopolysaccharide Induce Platelet-Leukocyte Aggregates and Tissue Factor Release, a Thrombotic Mechanism in Hemolytic Uremic Syndrome. <i>PLoS ONE</i> , 2009, 4, e6990.	1.1	113
16	Haemolytic uraemic syndrome. <i>Journal of Internal Medicine</i> , 2017, 281, 123-148.	2.7	108
17	Eculizumab treatment for rescue of renal function in IgA nephropathy. <i>Pediatric Nephrology</i> , 2014, 29, 2225-2228.	0.9	101
18	Uropathogenic <i>Escherichia coli</i> as a model of host-parasite interaction. <i>Current Opinion in Microbiology</i> , 2006, 9, 33-39.	2.3	98

#	ARTICLE	IF	CITATIONS
19	Multimeric Î± ₂ -Lactalbumin from Human Milk Induces Apoptosis through a Direct Effect on Cell Nuclei. <i>Experimental Cell Research</i> , 1999, 246, 451-460.	1.2	96
20	An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. <i>Pediatric Nephrology</i> , 2014, 29, 1967-1978.	0.9	95
21	A Novel Mechanism of Bacterial Toxin Transfer within Host Blood Cell-Derived Microvesicles. <i>PLoS Pathogens</i> , 2015, 11, e1004619.	2.1	95
22	Epidemiology, Clinical Presentation, and Pathophysiology of Atypical and Recurrent Hemolytic Uremic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 113-120.	1.5	91
23	Toll-Like Receptor 4 Promoter Polymorphisms: Common TLR4 Variants May Protect against Severe Urinary Tract Infection. <i>PLoS ONE</i> , 2010, 5, e10734.	1.1	90
24	Inherited Susceptibility to Acute Pyelonephritis: A Family Study of Urinary Tract Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 1227-1234.	1.9	86
25	A Genetic Basis of Susceptibility to Acute Pyelonephritis. <i>PLoS ONE</i> , 2007, 2, e825.	1.1	85
26	Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. <i>British Journal of Haematology</i> , 2007, 138, 651-662.	1.2	84
27	Mutation analysis and clinical implications of von Willebrand factorâ€“cleaving protease deficiency. <i>Kidney International</i> , 2003, 63, 1995-1999.	2.6	83
28	A common origin of the 4143insA ADAMTS13 mutation. <i>Thrombosis and Haemostasis</i> , 2006, 96, 3-6.	1.8	74
29	A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. <i>Molecular Immunology</i> , 2007, 44, 1835-1844.	1.0	73
30	Pathogen Specific, IRF3-Dependent Signaling and Innate Resistance to Human Kidney Infection. <i>PLoS Pathogens</i> , 2010, 6, e1001109.	2.1	68
31	The Antimicrobial Peptide Cathelicidin Protects Mice from Escherichia coli O157:H7-Mediated Disease. <i>PLoS ONE</i> , 2012, 7, e46476.	1.1	68
32	Shiga Toxinâ€“Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red Blood Cellâ€“Derived Microvesicles in Hemolytic Uremic Syndrome. <i>Journal of Immunology</i> , 2015, 194, 2309-2318.	0.4	65
33	Interleukinâ€“8 Receptor Deficiency Confers Susceptibility to Acute Pyelonephritis. <i>Journal of Infectious Diseases</i> , 2001, 183, S56-S60.	1.9	63
34	Crosstalk between the reninâ€“angiotensin, complement and kallikreinâ€“kinin systems in inflammation. <i>Nature Reviews Immunology</i> , 2022, 22, 411-428.	10.6	61
35	CYTOKINE REPERTOIRE OF EPITHELIAL CELLS LINING THE HUMAN URINARY TRACT. <i>Journal of Urology</i> , 1998, 159, 2185-2192.	0.2	60
36	Tissue Deposits of IgA-Binding Streptococcal M Proteins in IgA Nephropathy and Henoch-SchÃ¶nlein Purpura. <i>American Journal of Pathology</i> , 2010, 176, 608-618.	1.9	60

#	ARTICLE	IF	CITATIONS
37	Pathophysiology of Typical Hemolytic Uremic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2010, 36, 575-585.	1.5	59
38	Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy. <i>Journal of Immunology</i> , 2013, 191, 2184-2193.	0.4	59
39	Aliskiren inhibits renin-mediated complement activation. <i>Kidney International</i> , 2018, 94, 689-700.	2.6	53
40	Shiga Toxin Pathogenesis: Kidney Complications and Renal Failure. <i>Current Topics in Microbiology and Immunology</i> , 2011, 357, 105-136.	0.7	51
41	Neutrophil-Derived Proteinase 3 Induces Kallikrein-Independent Release of a Novel Vasoactive Kinin. <i>Journal of Immunology</i> , 2009, 182, 7906-7915.	0.4	50
42	Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions. <i>Advances in Experimental Medicine and Biology</i> , 2015, 865, 19-42.	0.8	48
43	Platelet Activation in Hemolytic Uremic Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 128-145.	1.5	47
44	The Combined Role of Galactose-Deficient IgA1 and Streptococcal IgA-binding M Protein in Inducing IL-6 and C3 Secretion from Human Mesangial Cells: Implications for IgA Nephropathy. <i>Journal of Immunology</i> , 2014, 193, 317-326.	0.4	47
45	A Novel C3 Mutation Causing Increased Formation of the C3 Convertase in Familial Atypical Hemolytic Uremic Syndrome. <i>Journal of Immunology</i> , 2012, 188, 2030-2037.	0.4	46
46	Enterohemorrhagic <i>Escherichia coli</i> Pathogenesis and the Host Response. <i>Microbiology Spectrum</i> , 2014, 2, .	1.2	42
47	Microvesicle transfer of kinin B1-receptors is a novel inflammatory mechanism in vasculitis. <i>Kidney International</i> , 2017, 91, 96-105.	2.6	42
48	The innate host response protects and damages the infected urinary tract. <i>Annals of Medicine</i> , 2001, 33, 563-570.	1.5	41
49	Shiga Toxin-Mediated Disease in MyD88-Deficient Mice Infected with <i>Escherichia coli</i> O157:H7. <i>American Journal of Pathology</i> , 2008, 173, 1428-1439.	1.9	41
50	Intestinal damage in enterohemorrhagic <i>Escherichia coli</i> infection. <i>Pediatric Nephrology</i> , 2011, 26, 2059-2071.	0.9	40
51	A novel mutation in the complement regulator clusterin in recurrent hemolytic uremic syndrome. <i>Molecular Immunology</i> , 2009, 46, 2236-2243.	1.0	39
52	Ouabain Protects against Shiga Toxin-Triggered Apoptosis by Reversing the Imbalance between Bax and Bcl-xL. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 1413-1423.	3.0	37
53	Fimbriae, Transmembrane Signaling, and Cell Activation. <i>Journal of Infectious Diseases</i> , 2001, 183, S47-S50.	1.9	36
54	Contact-system activation in children with vasculitis. <i>Lancet</i> , 2002, 360, 535-541.	6.3	35

#	ARTICLE	IF	CITATIONS
55	Antibodies to intimin and Escherichia coli secreted proteins A and B in patients with enterohemorrhagic Escherichia coli infections. <i>Pediatric Nephrology</i> , 2002, 17, 201-211.	0.9	35
56	Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab. <i>Pediatric Nephrology</i> , 2013, 28, 155-158.	0.9	35
57	Biologically active ADAMTS13 is expressed in renal tubular epithelial cells. <i>Pediatric Nephrology</i> , 2010, 25, 87-96.	0.9	34
58	Correct evaluation of renal glomerular filtration rate requires clearance assays. <i>Pediatric Nephrology</i> , 2002, 17, 847-851.	0.9	33
59	Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 3399-3403.	0.4	33
60	Cross-Reactive Protection against Enterohemorrhagic Escherichia coli Infection by Enteropathogenic E. coli in a Mouse Model. <i>Infection and Immunity</i> , 2011, 79, 2224-2233.	1.0	30
61	C1-Inhibitor Decreases the Release of Vasculitis-Like Chemotactic Endothelial Microvesicles. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2472-2481.	3.0	30
62	Microvesicle Involvement in Shiga Toxin-Associated Infection. <i>Toxins</i> , 2017, 9, 376.	1.5	29
63	Bernard-Soulier syndrome Karlstad: Trp 498*Stop mutation resulting in a truncated glycoprotein Ib α that contains part of the transmembranous domain. <i>British Journal of Haematology</i> , 1997, 98, 57-63.	1.2	28
64	Blockade of the kallikrein-kinin system reduces endothelial complement activation in vascular inflammation. <i>EBioMedicine</i> , 2019, 47, 319-328.	2.7	28
65	Increased platelet retention in familial recurrent thrombotic thrombocytopenic purpura. <i>Kidney International</i> , 1996, 49, 190-199.	2.6	25
66	ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. <i>European Journal of Pediatrics</i> , 2007, 166, 249-257.	1.3	25
67	Hyperfiltration evaluated by glomerular filtration rate at diagnosis in children with cancer. <i>Pediatric Blood and Cancer</i> , 2011, 56, 762-766.	0.8	25
68	Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2899-2907.	0.4	25
69	Human renal epithelial cells express iNOS in response to cytokines but not bacteria. <i>Kidney International</i> , 2002, 61, 444-455.	2.6	24
70	Orphan drug policies and use in pediatric nephrology. <i>Pediatric Nephrology</i> , 2017, 32, 1-6.	0.9	22
71	Phenotypic Expression of ADAMTS13 in Glomerular Endothelial Cells. <i>PLoS ONE</i> , 2011, 6, e21587.	1.1	19
72	Early Terminal Complement Blockade and C6 Deficiency Are Protective in Enterohemorrhagic <i>Escherichia coli</i> Infected Mice. <i>Journal of Immunology</i> , 2016, 197, 1276-1286.	0.4	19

#	ARTICLE	IF	CITATIONS
73	von Willebrand Factor Mediates Increased Platelet Retention in Recurrent Thrombotic Thrombocytopenic Purpura. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1456-1462.	1.8	19
74	Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. <i>Pediatric Nephrology</i> , 2009, 24, 447-458.	0.9	17
75	IgA nephropathy associated with a novel N-terminal mutation in factor H. <i>European Journal of Pediatrics</i> , 2011, 170, 107-110.	1.3	17
76	Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3669-3674.	0.4	17
77	Shiga Toxin-Bearing Microvesicles Exert a Cytotoxic Effect on Recipient Cells Only When the Cells Express the Toxin Receptor. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 212.	1.8	16
78	Extracellular vesicles in renal inflammatory and infectious diseases. <i>Free Radical Biology and Medicine</i> , 2021, 171, 42-54.	1.3	15
79	Haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. <i>Current Paediatrics</i> , 2002, 12, 569-574.	0.2	14
80	Factor D Inhibition Blocks Complement Activation Induced by Mutant Factor B Associated With Atypical Hemolytic Uremic Syndrome and Membranoproliferative Glomerulonephritis. <i>Frontiers in Immunology</i> , 2021, 12, 690821.	2.2	13
81	Successful thrombolysis of neonatal bilateral renal vein thrombosis originating in the IVC. <i>Pediatric Nephrology</i> , 2009, 24, 2069-2071.	0.9	12
82	Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism. <i>Scientific Reports</i> , 2019, 9, 14362.	1.6	12
83	Shiga Toxin Uptake and Sequestration in Extracellular Vesicles Is Mediated by Its B-Subunit. <i>Toxins</i> , 2020, 12, 449.	1.5	12
84	Innate Defences and Resistance to Gram Negative Mucosal Infection. , 2000, 485, 9-24.		11
85	Complement contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome. <i>Kidney International</i> , 2016, 90, 726-729.	2.6	11
86	The contact/kinin and complement systems in vasculitis. <i>Apmis</i> , 2009, 117, 48-54.	0.9	10
87	Annexin Induces Cellular Uptake of Extracellular Vesicles and Delays Disease in Escherichia coli O157:H7 Infection. <i>Microorganisms</i> , 2021, 9, 1143.	1.6	10
88	Antibody response to IgA-binding streptococcal M proteins in children with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 3434-3436.	0.4	8
89	Kinin system activation in vasculitis*. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2011, 100, 950-957.	0.7	2
90	Neutrophil Protease Cleavage of Von Willebrand Factor in Glomeruli – An Anti-thrombotic Mechanism in the Kidney. <i>EBioMedicine</i> , 2017, 16, 302-311.	2.7	2

#	ARTICLE	IF	CITATIONS
91	CYTOKINE REPERTOIRE OF EPITHELIAL CELLS LINING THE HUMAN URINARY TRACT. Journal of Urology, 1998, , 2185-2192.	0.2	2
92	IgG Binds Escherichia coli Serine Protease EspP and Protects Mice From E. coli O157:H7 Infection. Frontiers in Immunology, 2022, 13, 807959.	2.2	2
93	A role for complement blockade in kidney transplantation. , 2022, , .		2
94	Isolation and Characterization of Shiga Toxin-Associated Microvesicles. Methods in Molecular Biology, 2021, 2291, 207-228.	0.4	1
95	EnterohemorrhagicEscherichia coliPathogenesis and the Host Response. , 0, , 381-402.		1
96	A link between KrÃ¼ppel-like factor 4, complement activation, and kidney damage. Kidney International, 2022, 102, 14-16.	2.6	1
97	Factor H dysfunction contributes to platelet activation in hemolytic uremic syndrome (HUS). Molecular Immunology, 2007, 44, 191-192.	1.0	0
98	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Molecular Immunology, 2007, 44, 3971.	1.0	0
99	Anguish over angiopathy: Hemolytic uremic syndrome. Clinical Immunology, 2007, 122, 135-138.	1.4	0
100	Clinical and Complement Long-Term Follow-Up of a Pediatric Patient with C3 Mutation-Related Atypical Hemolytic Uremic Syndrome. Case Reports in Nephrology, 2018, 2018, 1-4.	0.2	0